Important Advancement for Patients with Muscle Invasive Bladder Cancer – Natera
Natera shared a post on LinkedIn:
“Today marks a proud moment for Naterans and an important advancement for patients with muscle invasive bladder cancer.
Together with our collaborators, we announced positive topline results from the IMvigor011 clinical trial. The study showed that Signatera-positive patients treated with Genentech’s immunotherapy, atezolizumab (Tecentriq), achieved statistically significant and clinically meaningful improvements in both disease-free survival and overall survival.
IMvigor011 is also the first prospective phase III study in muscle-invasive bladder cancer to be read out that uses a personalized, ctDNA MRD-guided approach — a first not just for Signatera, but for the field of ctDNA testing in bladder cancer.
We look forward to presenting trial data at an upcoming medical conference. Read more about this exciting announcement in our press release.”
More Posts Featuring Natera.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023